BIOGRAPHICAL SKETCH

NAME in English Yeh, Chau-Ting	POSITION TITLE Professor/ Director, Liver Research Center
NAME in Chinese 葉昭廷	

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	MM/YY	FIELD OF STUDY
University of Southern California, Ph.D.	Ph.D.	07/1988 ~ 08/1992	Molecular Microbiology
National Taiwan Univ. Taiwan	M.D.	07/1977 ~ 06/1984	Medical School
Chang Gung Memorial Hospital	Resident	07/1984 ~ 08/1987	Internal Medicine
Chang Gung Memorial Hospital	Fellow	08/1987 ~ 06/1993	Hepato-gastroenterology
Chang Gung University	Teaching assist.	08/1992 ~ 07/1996	Molecular and Cellular Biology
Chang Gung University	Associate professor	08/1996 ~ 07/2001	Hepato-gastroenterology
Chang Gung University	Professor	2001 / 08 ~迄今	Hepato-gastroenterology

A. Positions and Honors

Positions and Employment

1984-1987 Resident, Internal Medicine, Chang Gung Memorial Hospital
1987-1988 Chief Resident (F1), Dept. of GI, Chang Gung Memorial Hospital
1992-1993 Fellow (F2), Dept. of GI, Chang Gung Memorial Hospital
1993- Attending Doctor, Dept. of GI, Chang Gung Memorial Hospital
2001-2002 Director, Division of Hepatology, Department of GI, Chang Gung Memorial Hospital
2002-2004 Adjunct Investigator, Dept. of Biotechnology and Pharmaceutical Research, National Health Research Institutes
2004- Director, Digestive Core Lab, Liver Research Unit, Chang Gung Memorial Hospital
2007- Director, Liver Research Center, Chang Gung Memorial Hospital

Other Experience and Professional Memberships

2002-2006 Council member, Asian-Pacific Association for the Study of the Liver,
2004 Committee member, Public affair, The Gastroenterological Society of Taiwan,

Honors

1990 Professional Award, USC graduate school
1996 Professor宋瑞樓's Research Award
1998, 1999, 2000 National Science Council 甲種獎助

B. Selected Peer-reviewed Publications (2005-2010) (in chronological order)

1 Yeh CT, Tsao ML, Lin YC, Tseng IC. Identification of a novel single-stranded DNA fragment associated with human hepatitis. ***J. Infect. Dis.*** 2006 Apr 15;193(8):1089-97.

2 Yeh CT, Hsu CW, Chang ML, Sheen IS, Lin SM, Lin CJ, Lin CC, Chen YC, Chen JC. A novel ex vivo assay of interferon-based suppression, to predict the outcome of antiviral therapy for hepatitis C. ***J. Infect. Dis.*** 2006 May 15;193(10):1365-70.

3 Yeh CT, Lin WP, Hsu CW, Chang ML, Lin SM, Lin CC, Chen YC, Sheen IS. Emergence and takeover of precore-stop mutant prior to exacerbation of e antigen-negative chronic hepatitis B after withdrawal of lamivudine therapy. ***J. Med. Virol.*** 2006; 78: 906-10.

4 Hsu CW, Cheng JC, and Yeh CT (Correspondence). Quantitative assessment of serum NV-F viral DNA concentrations in patients coinfected with hepatitis B or C virus. ***J. Clin. Microbiol.*** 2006; 44: 3130-3.

5 Yeh CT, Chen TC, Chang ML, Hsu CW, Yeh TS, Lee WC, Huang SF, Tsai CC. Identification of NV-F virus DNA in hepatocellular carcinoma. ***J. Med. Virol.*** 2007; 79: 92-6.

6 Sheen IS, Tsou YK, Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC, Yeh CT (Correspondence). Nuclear HBcAg and histology activity index as independent predictors of the expression of singly spliced HBV-RNA. ***J. Viral Hepat.*** 2007; 14: 70-4.

7 Hsu CW, Yeh CT (Correspondence), Chang ML, Liaw YF. Identification of a hepatitis B virus S gene mutant in lamivudine treated patients experiencing HBsAg seroclearance. ***Gastroenterology*** 2007; 132: 543-550.

8 Yeh CT. (letter reply). ***Gastroenterology*** 2007; 132: 2617-8.

9. Chen RN, Huang YH, Yeh CT, Liao CH, Lin KH. Thyroid hormone receptors suppress pituitary tumor transforming gene 1 activity in hepatom. ***Cancer Res*** 2008; 68: 1697-706.

10. Chang ML, Chen JC, Yeh CT, Chang MY, Liang CK, Chiu CT, Lin DY, Liaw YF. Gene gun bombardment with DNA-coated gold particles is a potential alternative to hydrodynamics-based transfection for delivering genes into superficial hepatocytes. ***Hum Gene Ther.*** 2008; 19: 391-5.

11. Chen RN, Huang YH, Lin YC, Yeh CT, Liang Y, Chen SL, Lin KH. Thyroid hormone promotes cell invasion through activation of furin expression in human hepatoma cell lines. ***Endocrinology*** 2008; 149: 3817-31.

12. Yeh CT, Tang JH, Hsu CW, Chen YC, Chang ML, Lin CY. Expression of hepatitis B virus nuclear core antigen in young cirrhotic patients is associated with an unfavourable long-term outcome. ***J Viral Hepat***. 2008; Nov;15(11):839-48.

13. Wu CC, Peng PH, Chang YT, Huang YS, Chang KP, Hao SP, Tsang NM, Yeh CT, Chang YS, Yu JS. Identification of potential serum markers for nasopharyngeal carcinoma from a xenografted mouse model using Cy-dye labeling combined with three-dimensional fractionation. ***Proteomics***. 2008; 8(17): 3605-20

14. Yeh CT, Hsu CW, Chang ML, Tsao ML. Impact of the novel hepatotropic viruslike agent NV-F during chronic hepatitis C virus infection. ***J Infect Dis.*** 2008;198(12):1742-8.

15. Lai MW, Yeh CT (correspondence). The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant. ***Antivir Ther.*** 2008;13(7):875-9.

16. Yeh CT. Searching for molecular targets in HCC (review). ***Journal of the Chinese Oncology Society*** 2008;24(5):304-310.

17. Yeh CT. Is the NV-F agent a novel hepatitis virus? ***Future Microbiol*** 2009; 4(2):123-5.

18. Chang ML, Sung KF, Sheen IS, Lin SM, Yeh CT (correspondence). A liver slice culture-based ex vivo assay to predict the outcome of antiviral therapy for chronic hepatitis C. ***J Viral Hepat.*** 2009;16(5):359-66.

19. Lai MW, Huang SF, Hsu CW, Chang MH, Liaw YF, Yeh CT (correspondence). Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. ***Antivir Ther.*** 2009;14(2):249-61.

20. Liao CS, Tai PJ, Huang YH, Chen RN, Wu SM, Kuo LW, Yeh CT, Tsai MM, Chen WJ, Lin KH. Regulation of AKR1B1 by thyroid hormone and its receptors. ***Mol Cell Endocrinol.*** 2009;307:109-17.

21. Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. ***BMC Cancer.*** 2009;9:324.

22. Yeh CT, Hsu CW, Chen YC, Liaw YF. Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. ***J Clin Virol.*** 2009;45:114-8.
23. Wu SM, Huang YH, Lu YH, Chien LF, Yeh CT, Tsai MM, Liao CH, Chen WJ, Liao CJ, Cheng WL, Lin KH. Thyroid hormone receptor-mediated regulation of the methionine adenosyltransferase 1 gene is associated with cell invasion in hepatoma cell lines. ***Cell Mol Life Sci.*** 2010
24. Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy (review). ***Antivir Ther.*** 2010;15(3 Pt B):471-5.

C. Research Support

Ongoing Research Support

Name of Personnel	Title of Project	Role in Project	Project period (mm/yy)	Funding Agency
Chau-Ting Yeh	NV-F 全基因組之選殖 Molecular Cloning of the NV-F genome (NHRI-EX98-9811BI)	Principle Investigator	01/2009~12/2010	National Health Research Institutes
Chau-Ting Yeh	Investigation of the oncogenic potential of HBV drug resistant mutants 調查乙型肝炎病毒抗藥突變種的致癌潛力(NSC 98-3112-B-18A-004) (NSC 99-3112-B-18A-009)	Principle Investigator	05/2009~04/2011	National Science Council

Completed Research Support

Name of Personnel	Title of Project	Role in Project	Project period (mm/yy)	Funding Agency
Chau-Ting Yeh	Searching for down regulated genes in hepatoma tissue—Characterization of a novel bHLH-PAS protein that is under-expressed in hepatocellular carcinoma (NSC 91-3112-B-182-002-) (NSC 92-3112-B-182- 002-) (NSC 93-3112-B-182- 001-)	Principle Investigator	05/2002~04/2005	National Science Council
Chau-Ting Yeh	Cell culture adaptation of hepatitis C virus through authentic infection and replication in Huh-7 cells stably expressing Sip-L factor	Principle Investigator	08/2003~07/2006	National Science Council

	(NSC 92-2314-B-182-030-) (NSC 93-2314-B-182-012-) (NSC 94-2314-B-182-001-)			
Chau-Ting Yeh	Establishment of a Central Virological Lab for a clinicopathological network on hepatocellular carcinoma in Taiwan (DOH94-TD-G-111-032)	Principle Investigator	08/2005~ 07/2006	Department of Health
Chau-Ting Yeh	Identification of cellular factors capable of enhancing Sip-L assisted HCV replication (NSC 95-3112-B-182-008) (NSC96-3112-B-182-007) (NSC 97-3112-B-182-002)	Principle Investigator	05/2006~ 04/2009	National Research Program for Genomic Medicine
Chau-Ting Yeh	Clinical and basic characterization of a new hepatitis-associated agent (NSC95-2314-B-182-016-MY3)	Principle Investigator	08/2006~ 07/2009	National Science Council